You are here

  • Home
  • Archive
  • Volume 72, Issue 5
  • Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial

Article Text

Article menu
Download PDFPDF
Letters
Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial

https://doi.org/10.1136/annrheumdis-2012-202737

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors All authors contributed to the conception and design of the study and participated in the analysis and interpretation of the data. VR drafted the article and the other authors revised it critically for intellectual content. All authors approved the final version of this article.

    • Funding Competitive Research Funding of the Tampere University Hospital (Grant 9M124).

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval The ethics committees of all participating hospitals.

    • Provenance and peer review Not commissioned; externally peer reviewed.